Additional Hetero Ring Containing Patents (Class 546/187)
-
Patent number: 6262075Abstract: The present invention provides compounds of formula (I) and the pharmaceutically acceptable acid addition salts thereof, wherein X is a direct link or C1-C4 alkylene; and R is C3-C7 cycloalkyl optionally substituted by 1 or 2 substituents each independently selected from fluoro and C3-C7 cycloalkyl: with the proviso that X is not methylene when R is cyclopropyl, together with processes for the preparation of, intermediates used in the preparation of, compositions containing and uses of, such compounds. These compounds are useful as tachykinin antagonists.Type: GrantFiled: July 20, 1998Date of Patent: July 17, 2001Assignee: Pfizer IncInventors: Alexander Roderick MacKenzie, Allan Patrick Marchington, Donald Stuart Middleton, Sandra Dora Meadows
-
Publication number: 20010007038Abstract: The invention is a catalyst, the use of the catalyst and a method of using the catalyst in the formation of a compound with an amide bond.Type: ApplicationFiled: February 22, 2001Publication date: July 5, 2001Inventor: William Leonard Scott
-
Patent number: 6245761Abstract: This invention provides a series of substituted indoles which are useful in treating or preventing a condition associated with an excess of neuropeptide Y. This invention also provides the novel substituted indoles as well as pharmaceutical formulations with comprise as an active ingredient one or more of these substituted indoles.Type: GrantFiled: August 29, 1996Date of Patent: June 12, 2001Assignee: Eli Lilly and CompanyInventors: Thomas C. Britton, Robert F. Bruns, Jr., Donald R. Gehlert, Philip A. Hipskind, Karen L. Lobb, James A. Nixon, Paul L. Ornstein, Edward C. R. Smith, Hamideh Zarrinmayeh, Dennis M. Zimmerman
-
Patent number: 6242438Abstract: The present invention provides compounds of formula (I) and the pharmaceutically acceptable salts thereof. Such compounds and salts are tachykinin antagonists.Type: GrantFiled: June 1, 1998Date of Patent: June 5, 2001Assignee: Pfizer Inc.Inventors: Alexander Roderick MacKenzie, Allan Patrick Marchington, Donald Stuart Middleton, Sandra Dora Meadows
-
Patent number: 6225324Abstract: Compounds of formula I are useful antidepressant agents demonstrating potent inhibition of 5-HT reuptake. Z is selected from among various phenyl and hetaryl moieties while Y is benzyl or indolyl.Type: GrantFiled: December 21, 1999Date of Patent: May 1, 2001Assignee: Bristol-Myers Squibb CompanyInventors: Michael A. Poss, David R. Tortolani, Ronald J. Mattson, Joseph P. Yevich
-
Patent number: 6225309Abstract: The invention concerns compounds of formula (I), wherein each of G1, G2 and G3 is CH or N; m is 1 or 2; R1 includes hydrogen, halogeno and 1-C)alkyl; M1 is a group of formula: NR2—L1—T1R3, in which R2 and R3 together form a (1-4C)alylene group, L1 includes (1-4C)alkylene, and T1 is CH or N; A may be a direct link; M2 is a group of the formula: (T2R4)rL2—T3R5 in which R is 0 or 1, each of T2 and T3 is CH or N, each of R4 and R5 is hydrogen or (1-4C)alkyl, or R4 and R5 together form a (1-4C)alkylene group, and L2 includes (1-4C)alkylene; M3 may be a direct link to X; X includes sulphonyl; and Q includes naphthyl and a heterocyclic moiety; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use as antithrombotic or anticoagulant agents.Type: GrantFiled: August 9, 1999Date of Patent: May 1, 2001Assignee: Zeneca LimitedInventors: Alan Wellington Faull, Andrew Stocker, Colette Marie Mayo, John Preston
-
Patent number: 6218451Abstract: The present invention relates to the use of a photoreactive and UV absorbing piperidine compound of the formula A below and of a mixture consisting of this piperidine compound and at least one selected UV absorber as light stabilizers in coating materials, preferably in automotive coating materials. The invention also provides a method of stabilizing coating materials against the degradation of the polymer material present in the coating material, as induced by the action of atmospheric oxygen, heat and/or UV light, and the coating materials themselves that are stabilized in this way.Type: GrantFiled: October 12, 1998Date of Patent: April 17, 2001Assignee: Clariant Finance (BVI) LimitedInventors: Karl Bechtold, Gilbert Ligner
-
Patent number: 6218536Abstract: 1,2-Bis-adducts of stable hindered nitroxide compounds with substituted ethylenes are prepared by reacting two equivalents of nitroxyl compound with an ethylenically unsaturated compound such as styrene or an acrylate ester. These adducts are very effective inhibitors to prevent the premature polymerization of ethylenically unsaturated monomers when such monomers are distilled, processed or stored.Type: GrantFiled: October 7, 1998Date of Patent: April 17, 2001Assignee: Ciba Specialty Chemcials CorporationInventors: Glen Thomas Cunkle, Thomas F. Thompson, Volker H. von Ahn, Roland A. E. Winter
-
Patent number: 6211204Abstract: A compound of Formula (I): wherein R is independently selected from (CH2)9−12, (CH2CH2)2O, (CH2CH2)3O2, (CH2CH2)4O3, (CH2CH2)5O4, (CH2CH2)6O5 or (CH2CH2CH2)3O2; or an acid addition salt or hydrate thereof. The compounds, with improved water solubility, have unusually high affinity for muscarinic receptors, and exhibit agonist activity useful in the treatment of neurological and other disorders, in which stimulating cholinergic activity is desirable.Type: GrantFiled: January 14, 2000Date of Patent: April 3, 2001Assignee: University of ToledoInventors: William S. Messer, Yang Cao, Walajapet G. Rajeswaran
-
Patent number: 6211199Abstract: The present invention relates to novel substituted piperidine derivatives of formula (1), stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonist. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.Type: GrantFiled: December 15, 1997Date of Patent: April 3, 2001Assignee: Aventis Pharmaceuticals Inc.Inventors: John M. Kane, George D. Maynard, Timothy P. Burkholder, Larry D. Bratton, Christopher R. Dalton, Braulio Santiago, Elizabeth M. Kudlacz
-
Patent number: 6211228Abstract: Novel compounds, compositions and methods effective for the prevention and treatment of mast-cell mediated inflammatory disorders are described. The compounds, compositions and methods are effective for the prevention and treatment of inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis, as well as other types of immunomediated inflammatory disorders, such as rheumatoid arthritis, conjunctivitis and inflammatory bowel disease, various dermatological conditions, as well as certain viral conditions. The compounds comprise potent and selective inhibitors of the mast cell protease tryptase. The compositions for treating these conditions include oral, inhalant, topical and parenteral preparations as well as devices comprising such preparations.Type: GrantFiled: March 29, 1999Date of Patent: April 3, 2001Assignee: Axys Pharmaceuticals, IncInventors: Ken Duane Rice, Jeffrey Mark Dener, Anthony Robert Gangloff, Elaine Yee-Lin Kuo
-
Patent number: 6207680Abstract: Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. The compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amount of one of the compounds. Depot derivatives of the compounds are useful for providing long acting effects of the compounds. The compounds are also useful as analgesics by administering a pain-relieving effective amount of one of the compounds to a mammal.Type: GrantFiled: June 6, 1995Date of Patent: March 27, 2001Assignee: Aventis Pharmaceuticals Inc.Inventors: Edward J. Glamkowski, Yulin Chiang, Joseph T. Strupczewski, Kenneth J. Bordeau, Peter A. Nemoto, John J. Tegeler
-
Patent number: 6201047Abstract: The invention relates to the use of piperidine compounds of the formula I in which R1 is hydroxyl, lower alkyl, lower alkoxy, R2 is a substituted or unsubstituted, mono- or bicyclic radical of aromatic type, R3 is oxygen, —NH— or —N(C1-4-alkyl)- and R8 independently at each occurrence is hydrogen or methyl for preparing light-stabilized, EPDM-modified polypropylene which is employed in particular in automotive construction, such as for shock absorbers, cover strips and the like. A further subject of the invention is the combination of abovementioned piperidine compounds with known UV absorbers. The invention also relates to EPDM-modified polypropylene which contains from 0.05 to 2.5% by weight, preferably from 0.1 to 0.6% by weight, of a radical of a compound of the above formula I, and to products produced therefrom.Type: GrantFiled: February 17, 1998Date of Patent: March 13, 2001Assignee: Clariant Fianance (BVI) LimitedInventors: Lajos Avar, Andreas Thuermer, Gilbert Ligner
-
Patent number: 6172062Abstract: This invention relates to certain 5-HT4 receptor modulators, particularly 5-HT4 receptor antagonists, represented by Formula I: wherein Z is formula (A) or (B): wherein R1, R2, R3, R4, and R5 and the other substituents are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds and methods for their use as therapeutic agents.Type: GrantFiled: September 2, 1999Date of Patent: January 9, 2001Assignee: Syntex (USA) LLCInventors: Robin Douglas Clark, Alam Jahangir
-
Patent number: 6172073Abstract: A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.Type: GrantFiled: March 27, 1998Date of Patent: January 9, 2001Assignee: Eli Lilly and CompanyInventors: James E. Audia, David J. Hibschman, Joseph H. Krushinski, Jr., Thomas E. Mabry, Jeffrey S. Nissen, Kurt Rasmussen, Vincent P. Rocco, John M. Schaus, Dennis C. Thompson, David T. Wong
-
Patent number: 6172067Abstract: A compound of the formula: or a pharmaceutically acceptable salt thereof, wherein R is unsubstituted, mono-, di- or tri-substituted (C3-C11)cycloalkyl or (C3-C11)cycloalkenyl or the like, A is unsubstituted (C1-C7)alkyl or (C2-C5 )alkenyl, or unsubstituted, mono-, di- or tri-substituted aryl, or aromatic-heterocyclic or the like, Y is hydrogen, halo, amino or mercapto, or unsubstituted, mono-, di- or tri- substituted (C1-C10)alkyl-M—, (C3-C7)cycloalkyl-M—, (C2-C6)alkenyl-M—, (C1-C4)alkyl-NH-((C1-C4)alkyl)-M—, di(C1-C4)alkyl-N-((C1-C4)alkyl)-M—, aryl-M—, aromatic or non-aromatic heterocyclic-M—, aryl-(C1-C5)alkyl-M— or aromatic non-aromatic heterocyclic-(C1-C5)alkyl-M—, wherein M is a covalent bond O, S, NH or the like, or the like; Z1, Z2, Z3 and Z4 are hydrogen or the like, has ORL1-receptor agonist activity, and are useful as analgesics or the like in mammalian subjects.Type: GrantFiled: August 5, 1999Date of Patent: January 9, 2001Assignee: Pfizer Inc.Inventors: Fumitaka Ito, Hirohide Noguchi, Hiroshi Kondo
-
Patent number: 6169097Abstract: The present invention concerns compounds of formula the N-oxide forms, the pharmaceutically acceptable addition salts and stereochemically isomeric forms thereof, wherein n is 0, 1 or 2; m is 1 or 2, provided that if m is 2, then n is 1; p is 0, 1 or 2; ═Q is ═O or ═NR3; X is a covalent bond or a bivalent radical of formula —O—, —S—, —NR3—; R1 is Ar1; Ar1C1-6alkyl or di(Ar1)C1-6alkyl, wherein each C1-6alkyl group is optionally substituted with hydroxy, C1-4alkyloxy, oxo or a ketalized oxo substituent of formula —O—CH2—CH2—O— or —O—CH2—CH2—CH2—O—; R2 is Ar2; Ar2C1-6alkyl; Het or HetC1-6alkyl; R3 is hydrogen or C1-6alkyl; R4 is hydrogen; C1-4alkyl; C1-4aklyloxyC1-4alkyl; hydroxyC1-4alkyl; carboxyl; C1-4aklyloxycarbonyl or Ar3; R5 is hydrogen; hydroxy; Ar3; Ar3C1-6alkyloxy; di(Ar3)C1-6alkyloxy; Ar3C1-6alkylthio; di(Ar3)C1-6alkylthio; Ar3C1-6alkylsulfoxy; di(Ar3)C1-6alkylsulfoxy;Type: GrantFiled: June 22, 1998Date of Patent: January 2, 2001Assignee: Janssen Pharmaceutica N.V.Inventors: Frans Eduard Janssens, François Maria Sommen, Dominique Louis Nestor Ghislaine Surleraux, Yves Emiel Maria Van Roosbroeck
-
Patent number: 6166037Abstract: The present invention is directed to pyrrolidine and piperidine compounds of the formula I: ##STR1## (wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4a, R.sup.4b, R.sup.4c, R.sup.4d, R.sup.4e, R.sup.4f, R.sup.4g, R.sup.4h, m, n, x and y are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, and/or CXCR-4.Type: GrantFiled: August 27, 1998Date of Patent: December 26, 2000Assignee: Merck & Co., Inc.Inventors: Richard J. Budhu, Edward Holson, Jeffrey J. Hale, Christopher Lynch, Malcolm Maccoss, Scott C. Berk, Sander G. Mills, Christopher A. Willoughby
-
Patent number: 6166011Abstract: Compounds of formula (I), their salts and solvates, wherein the substituents are as described herein, are FKBP inhibitors.Type: GrantFiled: July 15, 1999Date of Patent: December 26, 2000Assignee: Pfizer IncInventors: Martin J. Wythes, Michael J. Palmer, Mark I. Kemp, Malcolm C. MacKenny, Robert J. Maguire, James F. Blake, Jr.
-
Patent number: 6166033Abstract: This invention provides a 2-carbonylthiazole derivative represented by formula (I): ##STR1## wherein each of Ar.sup.1 and Ar.sup.2 represents a phenyl group or a substituted phenyl group; R.sup.1 represents an alkoxy group having 1 to 5 carbon atoms, a hydroxyl group or an amino group; Y.sup.1 --Y.sup.2 represents CH--CO or C.dbd.CR.sup.2, wherein R.sup.2 represents a hydrogen atom or an alkyl group having 1 to 5 carbon atoms; and n is an integer of from 1 to 4, or a pharmaceutically acceptable salt thereof. The disclosed compounds are useful as drugs for preventing and treating dopamine D receptor-related morbid states such as schizophrenia and problematic behavior caused by cerebrovascular accidents and senile dementia and do not induce extrapyramidal disorders as side effects.Type: GrantFiled: November 5, 1999Date of Patent: December 26, 2000Assignees: Taisho Pharmaceutical Co., Ltd., Nihon Nohyaku Co., Ltd.Inventors: Atsuro Nakazato, Toshihito Kumagai, Shigeyuki Chaki, Kazuyuki Tomisawa, Masashi Nagamine, Makoto Gotoh, Masanori Yoshida
-
Patent number: 6150527Abstract: New compounds are disclosed for multimerizing immunophilins and proteins containing immunophilin or immunophilin-related domains.Type: GrantFiled: February 28, 1997Date of Patent: November 21, 2000Assignee: Ariad Pharmaceuticals, Inc.Inventors: Dennis A. Holt, Terence P. Keenan, Tao Guo, Edgardo Laborde, Wu Yang
-
Patent number: 6136826Abstract: The present invention relates to novel peripheral vasodilating agents characterized by each containing as an active ingredient, a piperidine derivative or pharmaceutically acceptable salt thereof having excellent peripheral vasodilating activity.Said piperidine derivative or pharmaceutically acceptable salt thereof is represented by the general formula (1): ##STR1## (wherein R, R.sup.1 and R.sup.2 are the same as defined above.Type: GrantFiled: April 28, 1998Date of Patent: October 24, 2000Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Takafumi Fujioka, Shuji Teramoto, Michinori Tanaka, Hiroshi Shimizu, Fujio Tabusa, Michiaki Tominaga
-
Patent number: 6133262Abstract: This application relates to novel compounds of formula I (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula I, and the use of the compounds of formula I as thrombin inhibitors.Type: GrantFiled: October 28, 1999Date of Patent: October 17, 2000Assignee: Eli Lilly and CompanyInventors: Jefferson Ray McCowan, John Eldon Toth, Daniel Jon Sall
-
Patent number: 6133290Abstract: The present invention relates to a compound of formula I: ##STR1## or a pharmaceutical acid addition salt thereof; which are useful for activating 5-HT.sub.1F receptors and inhibiting neuronal protein extravasation in a mammal.Type: GrantFiled: June 16, 1999Date of Patent: October 17, 2000Assignee: Eli Lilly and CompanyInventors: Joseph Herman Krushinski, Jr., John Mehnert Schaus
-
Patent number: 6133456Abstract: New compounds are disclosed for multimerizing immunophilins and proteins containing immunophilin or immunophilin-related domains. The compounds are of the formulaM.sup.1 --L--M.sup.2where M.sup.1 and M.sup.2 are independently moieties of the formula: ##STR1## in which B.sup.1, B.sup.2, B.sup.3, R.sup.1, R.sup.2, n, W, X and Y are as defined.Type: GrantFiled: February 28, 1997Date of Patent: October 17, 2000Assignee: ARIAD Gene Therapeutics, Inc.Inventors: Dennis A. Holt, Terence P. Keenan, Tao Guo, Edgardo Laborde, Wu Yang
-
Patent number: 6130101Abstract: The present invention describes xanthene dyes, including rhodamines, rhodols and fluoresceins that are substituted one or more times by a sulfonic acid or a salt of a sulfonic acid. The dyes of the invention, including chemically reactive dyes and dye-conjugates are useful as fluorescent probes, particularly in biological samples.Type: GrantFiled: September 23, 1997Date of Patent: October 10, 2000Assignee: Molecular Probes, Inc.Inventors: Fei Mao, Wai-Yee Leung, Richard P. Haugland
-
Patent number: 6124316Abstract: A compound of formula: ##STR1## in which: Ar represents a pyrid-2-yl or a phenyl which is unsubstituted or substituted by a halogen, a methyl or a (C.sub.1 -C.sub.4)alkoxy;R.sub.1 represents a methyl group;R.sub.11 represents hydrogen;or R.sub.1 and R.sub.11 together represent a --(CH.sub.2).sub.3 -- group;R.sub.2 represents a hydroxyl; a (C.sub.1 -C.sub.7)alkoxy; a (C.sub.1 -C.sub.7)acyloxy; a cyano; an --NR.sub.6 R.sub.7 group; an --NR.sub.3 COR.sub.4 group; an --NR.sub.3 COOR.sub.8 group; an --NR.sub.3 SO.sub.2 R.sub.9 group; an --NR.sub.3 CONR.sub.10 R.sub.12 group; a (C.sub.1 -C.sub.7)acyl group; a (C.sub.1 -C.sub.7)alkoxycarbonyl; a --CONR.sub.10 R.sub.12 group; a --CH.sub.2 OH group; a (C.sub.1 -C.sub.7)alkoxymethyl; a (C.sub.1 -C.sub.7)acyloxymethyl; a (C.sub.1 -C.sub.7)alkylaminocarbonyloxymethyl; a --CH.sub.2 NR.sub.13 R.sub.14 group; a --CH.sub.2 NR.sub.3 COR.sub.4 group; a --CH.sub.2 NR.sub.3 COOR.sub.8 group; a --CH.sub.2 NR.sub.3 SO.sub.2 R.sub.9 group; a --CH.sub.2 NR.sub.3 CONR.sub.10 R.sub.Type: GrantFiled: May 7, 1999Date of Patent: September 26, 2000Assignee: SanofiInventors: Daniel Bichon, Patrick Gueule, Didier Van Broeck, Xavier Emonds-Alt, Vincenzo Proietto
-
Patent number: 6110936Abstract: The invention concerns a compound of formula (I), ##STR1## wherein, for example: R.sup.1 is of the formula --NHC(.dbd.O) (1-4C) alkyl; R.sup.2 and R.sup.3 are hydrogen or fluoro; R.sup.4 and R.sup.5 are hydrogen or methyl; >A--B-- is of the formula >C.dbd.CH--, >CHCH.sub.2, or >C(OH)CH.sub.2 -- (> represents two single bonds); D is O, S, SO, SO.sub.2 or --NR.sup.7 ; wherein R.sup.7 is hydrogen, R.sup.10 CO--, R.sup.10 SO.sub.2 --, R.sup.a OC(R.sup.b).dbd.CH(C.dbd.O)--, R.sup.c C(.dbd.O)C(.dbd.O)--, R.sup.d N.dbd.C(R.sup.e)C(.dbd.O)--, R.sup.f NHC(R.sup.g).dbd.CHC(.dbd.O)-- or R.sup.14 CH(R.sup.13)(CH.sub.2).sub.m --; wherein R.sup.10 is (1-6 C)alkyl [optionally substituted by, for example, hydroxy or (1-6 C)alkanoyl], R.sup.11 C(O)O(1-6 C)alkyl or R.sup.12 O--; wherein R.sup.11 is optionally substituted (1-6 C)alkyl; R.sup.12 is optionally substituted (1-6 C)alkyl; R.sup.a, R.sup.b, R.sup.c, R.sup.d, R.sup.e, R.sup.f, R.sup.g are (1-6 C)alkyl; m is 0 or 1; R.sup.13 is cyano; R.sup.Type: GrantFiled: January 19, 1999Date of Patent: August 29, 2000Assignee: Zeneca LimitedInventor: Michael Barry Gravestock
-
Patent number: 6110939Abstract: This invention concerns the compounds of formula the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is 0, 1 or 2; m is 1 or 2, provided that if m is 2, then n is 1; X is a covalent bond or a bivalent radical of formula --O--, --S--, --NR.sup.3 --; .dbd.Q is .dbd.O or .dbd.NR.sup.3 ; R.sup.1 is Ar.sup.1, Ar.sup.1 C.sub.1-6 alkyl or di(Ar.sup.1)C.sub.1-6 alkyl wherein the C.sub.1-6 alkyl group is optionally substituted; R.sup.2 is Ar.sup.2, Ar.sup.2 C.sub.1-6 alkyl, Het or HetC.sub.1-6 alkyl; L is a benzimidazole or imidazopyridine derivative of formula (A) or (B) Ar.sup.1 is optionally substituted phenyl Ar.sup.2 is naphtalenyl or optionally substituted phenyl; and Het is an optionally substituted monocyclic or bicyclic heterocycle; as substance P antagonists; their preparation, compositions containing them and their use as a medicine.Type: GrantFiled: June 19, 1998Date of Patent: August 29, 2000Assignee: Janssen Pharmaceutica N.V.Inventors: Frans Eduard Janssens, Fran.cedilla.ois Maria Sommen, Dominique Louis Nester Ghislaine Surleraux, Joseph Elisabeth Leenaerts
-
Patent number: 6090824Abstract: Compounds of formula I ##STR1## wherein Q.sup.1, Q.sup.2, Q.sup.3, and Q.sup.4 have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists Substance P and NKA, useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.Type: GrantFiled: November 14, 1996Date of Patent: July 18, 2000Assignee: Zeneca LimitedInventors: Peter R. Bernstein, Bruce T. Dembofsky
-
Patent number: 6083950Abstract: Novel piperzine derivatives substituted on one nitrogen by an aromatic system and on the other nitrogen by (2,5-dioxopyrrolidin)-1-yl) alkanes or (2,6-dioxopiperidin-1-yl) alkanes have been found to exhibit selective .alpha..sub.1A adrenergic activity. The compounds are useful for treatment of disease conditions, such as peripheral vascular disease, congestive heart failure, hypertension and especially benign prostatic hypertrophy.Type: GrantFiled: July 21, 1998Date of Patent: July 4, 2000Assignee: Ranbaxy Laboratories LimitedInventors: Nitya Anand, Neelima Sinha, Sanjay Jain, Anita Mehta, Jang Bahadurgupta
-
Patent number: 6075038Abstract: This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as selective alpha-1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing orthostatic hypotension. One such tissue is found surrounding the urethral fining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.Type: GrantFiled: December 4, 1997Date of Patent: June 13, 2000Assignee: Merck & Co., Inc.Inventors: Michael A. Patane, Mark G. Bock, Roger M. Freidinger
-
Patent number: 6069254Abstract: Carboxamide derivatives of pyrrolidine, piperidine, and hexahydroazepine of formula (I): ##STR1## are disclosed as useful in treating platelet-mediated thrombotic disorders.Type: GrantFiled: April 29, 1997Date of Patent: May 30, 2000Assignee: Ortho Pharmaceutical Corp.Inventors: Michael J. Costanzo, William J. Hoekstra, Bruce E. Maryanoff
-
Patent number: 6066637Abstract: The present invention provides compounds represented by the general formula (1) whereinR.sub.1 is selected from H, OH, OR.sub.2 or halogen (F, Cl, Br, I);R.sub.2 is lower alkyl (C.sub.1 to C.sub.6);n is selected from 0, 1 or 2;X is CH or CH.sub.2 ;m is selected from 2, 3 or 4;Y is N or CH.sub.2 ;Ar is aryl or heteroaryl, both optionally substituted;or pharmaceutically acceptable salts thereof, as well as methods and pharmaceutical compositions utilizing these compounds for the inhibition of serotonin uptake and the treatment of CNS disorders, particularly depression.Type: GrantFiled: April 23, 1999Date of Patent: May 23, 2000Assignee: American Home Products CorporationInventors: Michael G. Kelly, Young H. Kang
-
Patent number: 6066636Abstract: Heterocyclic derivatives of di-N-substituted piperazine or 1,4 di-substituted piperidine compounds in accordance with formula I (including all isomers, salts and solvates) ##STR1## wherein wherein one of Y and Z is --N-- and the other is --N-- or --CH--;X is --O--, --S--, --SO--, --SO.sub.2 -- or --CH.sub.2 --;Q is ##STR2## R is alkyl, cycloalkyl, optionally substituted aryl or heteroaryl; R.sup.1, R.sup.2 and R.sup.3 are H or alkyl;R.sup.4 is alkyl, cycloalkyl or ##STR3## R.sup.5 is H, alkyl, --C(O)alkyl, arylcarbonyl, --SO.sub.2 alkyl, aryl-sulfonyl --C(O)Oalkyl, aryloxycarbonyl, --C(O)NH-alkyl or aryl-aminocarbonyl, wherein the aryl portion is optionally substituted;R.sup.6 is H or alkyl; andR.sup.7 is H, alkyl, hydroxyalkyl or alkoxyalkyl; are muscarinic antagonists useful for treating cognitive disorders such as Alzheimer's disease.Type: GrantFiled: June 28, 1999Date of Patent: May 23, 2000Assignee: Schering CorporationInventors: Joseph A. Kozlowski, Stuart W. McCombie, Jayaram R. Tagat, Susan F. Vice
-
Patent number: 6063926Abstract: Compounds within the genus represented by the structural formula I ##STR1## or a pharmaceutically acceptable salt thereof, wherein: T is substituted phenyl or substituted pyridyl; ##STR2## R.sup.4 is methyl or ethyl; and Z is substituted piperidinyl.Type: GrantFiled: November 18, 1998Date of Patent: May 16, 2000Assignee: Schering CorporationInventors: Gregory A. Reichard, Cheryl A. Alaimo, Neng-Yang Shih, Pauline C. Ting, Nicholas I. Carruthers, Brian J. Lavey
-
Patent number: 6051570Abstract: This invention particularly relates to novel pyridylmethylsulfinyl benzimidazole represented by the general formula (I), its tautomers, its derivatives, its analogs, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates and pharmaceutical compositions containing them and the use thereof. ##STR1## The present invention also relates to a process for the preparation of the above said novel pyridylmethylsulfinyl benzimidazoles and pharmaceutical compositions containing them.Type: GrantFiled: March 10, 1998Date of Patent: April 18, 2000Assignees: Dr. Reddy's Research Foundation, Reddy-Cheminor, Inc.Inventors: Braj Bhushan Lohray, Vidya Bhushan Lohray, Prasuna Guntupalli, Narayan Reddy Kommireddi, Prem Kumar Mamnoor, Rajagopalan Ramanujam
-
Patent number: 6043255Abstract: Di-N-substituted piperazine or 1,4 di-substituted piperadine compounds in accordance with formula I (including all isomers, salts, esters, and solvates) ##STR1## wherein R, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.21, R.sup.27, R.sup.28, X, Y, and Z are as defined herein are muscarinic antagonists useful for treating cognitive disorders such as Alzheimer's disease. Pharmaceutical compositions and methods of preparation are also disclosed. Also disclosed are synergistic combinations of compounds of the above formula with acetylcholinesterase inhibitors.Type: GrantFiled: March 10, 1999Date of Patent: March 28, 2000Assignee: Schering CorporationInventors: Derek B. Lowe, Wei K. Chang, Joseph A. Kozlowski, Joel G. Berger, Robert McQuade, Allen Barnett, Margaret Sherlock, Wing Tom, Sundeep Dugar, Lian-Yong Chen, John W Clader, Samuel Chackalamannil, Yuguang Wang, Stuart W. McCombie, Jayaram R. Tagat, Susan F. Vice, Wayne Vaccaro, Michael J. Green, Margaret E. Browne, Theodros Asberom, Craig D. Boyle
-
Patent number: 6040316Abstract: The small nonpeptides of the instant invention are tachykinin antagonists of formula ##STR1## or a pharmaceutically acceptable salt thereof wherein: R.sub.1 is straight or branched alkyl of from 5 to 15 carbon atoms, aryl, or heteroaryl;R.sub.2 is hydrogen, hydroxy, amino, or thiol;R.sub.3 is aryl, arylsulfonylmethyl, or saturated or unsaturated heterocycle;R.sub.4 is from 1 to 4 groups each independently selected from halogen, alkyl, hydroxy, and alkoxy;n is an integer of from 2 to 6; and the carbon atom of (CH.sub.2).sub.n group can be replaced by oxygen, nitrogen, or sulphur. The compounds are highly selective and functional NK.sub.3 antagonists expected to be useful in the treatment of pain, depression, anxiety, panic, schizophrenia, neuralgia, addiction disorders, inflammatory diseases, gastrointestinal disorders, vascular disorders, and neuropathological disorders.Type: GrantFiled: January 22, 1998Date of Patent: March 21, 2000Assignee: Warner-Lambert CompanyInventors: Michael Huai Gu Chen, Fu-Zon Chung, Helen Tsenwhei Lee
-
Patent number: 6037352Abstract: Di-N-substituted piperazine or 1,4 di-substituted piperadine compounds in accordance with formula I (including all isomers, salts, esters, and solvates) ##STR1## wherein R, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.21, R.sup.27, R.sup.28, X, Y, and Z are as defined herein are muscarinic antagonists useful for treating cognitive disorders such as Alzheimer's disease. Pharmaceutical compositions and methods of preparation are also disclosed. Also disclosed are synergistic combinations of compounds of the above formula or other compounds capable of enhancing acetylcholine release with acetylcholinesterase inhibitors.Type: GrantFiled: November 19, 1998Date of Patent: March 14, 2000Assignee: Schering CorporationInventors: Derek Lowe, Wei Chang, Joseph Kozlowski, Joel G. Berger, Robert McQuade, Allen Barnett, Margaret Sherlock, Wing Tom, Sundeep Dugar, Lian-Yong Chen, John W Clader, Samuel Chackalamannil, Wang Yuguang, Stuart W. McCombie, Jayaram R. Tagat, Susan F. Vice, Wayne Vaccaro, Michael J. Green, Margaret E. Browne, Theodros Asberom
-
Patent number: 6034082Abstract: Compounds of formula (I) ##STR1## and salts thereof, wherein: R.sup.1 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.3 -C.sub.7 cycloalkyl(C.sub.1 -C.sub.4)alky aryl or aryl(C.sub.1 -C.sub.4)alkyl; wherein the C.sub.1 -C.sub.6 alkyl group is optionally substituted by fluorine and the C.sub.3 -C.sub.7 cycloalkyl or C.sub.3 -C.sub.7 cycloalkyl(C.sub.1 -C.sub.4)alkyl group is optionally substituted in the cycloalkyl ring by up to two substituents each independently selected from halo, C.sub.1 -C.sub.4 alkoxy or halo(C.sub.1 -C.sub.4)alkoxy; R.sup.2 is phenyl optionally substituted with one or two halo substituents or is indolyl, thienyl, benzothienyl or naphthyl; R.sup.3 is NH.sub.2,--NR.sup.4 SO.sub.2 (C.sub.1 -C.sub.6 alkyl), --NR.sup.4 SO.sub.2 aryl, --NR.sup.4 SO.sub.2 N(R.sup.4).sub.2, NR.sup.4 CO(C.sub.1 -C.sub.6 alkyl), --NR.sup.4 CO aryl or a group or formula (a) ##STR2## wherein W is O, NR.sup.5, CH(OH), CHCO.sub.2 H, CHN(R.sup.4).sub.2, CHF, CF.sub.2, C.dbd.O or CH.sub.2 ; R.sup.Type: GrantFiled: May 13, 1998Date of Patent: March 7, 2000Assignee: Pfizer Inc.Inventors: Alexander Roderick MacKenzie, Allan Patrick Marchington, Donald Stuart Middleton, Sandra Dora Meadows
-
Patent number: 6028082Abstract: Compounds of formula (I), a method for obtaining them and pharmaceutical compositions containing them are described. The compounds are useful as human NK.sub.3 receptor antagonists.Type: GrantFiled: March 12, 1998Date of Patent: February 22, 2000Assignee: Sanofi-SynthelaboInventors: Daniel Bichon, Xavier Emonds-Alt, Patrick Gueule, Vincenzo Proietto, Didier Van Broeck
-
Patent number: 6025378Abstract: The bicyclic heterocyclic compounds are prepared by reaction of correspondingly substituted carboxylic acids with amines, in particular with phenylglycinolamine. The bicyclic heterocyclic compounds according to the invention are suitable as active compounds in medicaments, in particular in medicaments having an antiatherosclerotic action.Type: GrantFiled: June 18, 1998Date of Patent: February 15, 2000Assignee: Bayer AktiengesellschaftInventors: Richard Connell, Siegfried Goldmann, Ulrich Muller, Stefan Lohmer, Hilmar Bischoff, Dirk Denzer, Rudi Grutzmann, Stefan Wohlfeil
-
Patent number: 6025385Abstract: This invention relates to a taxane derivative represented by the following formula (1): wherein at least one of X and Y represents a group --CO--A--B in which A represents a single bond, an alkylenecarbonyl group or the like and B represents a substituted or unsubstituted piperidino group or the like, the other represents a tert-butoxycarbonyl group or the like, and Z represents a hydrogen atom or a triethylenesilyl group, and also to a drug containing the same.This compound has high solubility in water and also has excellent antitumor activities.Type: GrantFiled: January 14, 1999Date of Patent: February 15, 2000Assignee: Kabushiki Kaisha Yakult HonshaInventors: Hideaki Shimizu, Atsuhiro Abe, Takashi Yaegashi, Seigo Sawada, Hiroshi Nagata
-
Patent number: 6025372Abstract: Somatostatin agonist compounds of formula I are disclosed: ##STR1## including pharmaceutically acceptable salts and hydrates thereof These compounds are useful in the treatment of diabetes, cancer, acromegaly, restenosis, depression, irritable bowel syndrome and pain. The compounds are potent with high selectivity toward the receptor subtype 2.Pharmaceutical compositions and methods of treatment are also included.Type: GrantFiled: April 1, 1998Date of Patent: February 15, 2000Assignee: Merck & Co., Inc.Inventors: Lihu Yang, Arthur A. Patchett, Alexander Pasternak, Kevin Chapman, James R. Tata, Liangqin Guo
-
Patent number: 6017930Abstract: This invention provides methods for the treatment or prevention of interstitial cystitis or urethral syndrome in a mammal which comprise administering to a mammal in need thereof an effective amount of a compound of formula (I), where R.sup.1 and R.sup.2 are independently selected from the group consisting of hydrogen, methyl, methoxy, chloro, and trifluoromethyl, with the proviso that no more than one of R.sup.1 and R.sup.2 can be hydrogen; and Y is (1), (2), (3), (4), (5), (6), N--R.sup.a, or CH--NR.sup.b R.sup.c, where R.sup.a, R.sup.b, and R.sup.c are independently selected from the group consisting of hydrogen and C.sub.1 -C.sub.6 alkyl; or a pharmaceutically acceptable salt or solvate thereof.Type: GrantFiled: August 25, 1998Date of Patent: January 25, 2000Assignee: Eli Lilly and CompanyInventors: Smriti Iyengar, Mark A. Muhlhauser, Karl B. Thor
-
Patent number: 6013803Abstract: The invention relates to a process for reducing the dimerization of piperidines of the formula I ##STR1## where R.sup.1 to R.sup.4 are C.sub.1 - to C.sub.6 -alkyl, R.sup.1 and R.sup.2 and/or R.sup.3 and R.sup.4 together are a CH.sub.2 chain having 2 to 5 carbon atoms, which comprises adding to the piperidine from 0.001 to 0.2% by weight of a reducing agent of the formula MXH.sub.4-m Y.sub.m, where M is an alkali metal, NR.sub.4, where R are identical or different C.sub.1 -C.sub.4 -alkyl groups, or an equivalent of an alkaline earth metal or an equivalent of zinc, X is boron or aluminum, Y is H or CN and m is 0 or 1. The invention also relates to a mixture of piperidines of the formula I, from 0.001 to 0.2% by weight of a reducing agent and from 1 to 1000 ppm of dimers of the piperidines of the formula I, and to the preparation of hindered amine light stabilizers therefrom.Type: GrantFiled: November 12, 1998Date of Patent: January 11, 2000Assignee: BASF AktiengesellschaftInventors: Manfred Julius, Harald Rust, Alfred Krause, Hardo Siegel, Wolfgang Siegel, Tom Witzel
-
Patent number: 6011157Abstract: A process for purifying crude piperidines of the formula I ##STR1## where R.sup.1 to R.sup.4 are C.sub.1 -C.sub.6 -alkyl, or R.sup.1 and R.sup.2 and/or R.sup.3 and R.sup.4 together are a CH.sub.2 -chain of 2 to 5 carbons, which comprises, in a first step, removing high-boiling substances and, if present, water from the crude piperidines by distillation; in a second step, adding from 0.01 to 5% by weight, based on the product of the first step, as a reducing agent; and, in a third step, isolating the piperidines by distillation.Type: GrantFiled: November 12, 1998Date of Patent: January 4, 2000Assignee: BASF AktiengesellschaftInventors: Manfred Julius, Harald Rust, Alfred Krause, Hardo Siegel, Wolfgang Siegel, Tom Witzel
-
Patent number: 6008213Abstract: Compounds of formula (I) ##STR1## wherein A.sub.1 is C or N; E is a five- or six-membered heteroaromatic or six-membered aromatic ring optionally substituted by R.sup.3 or R.sup.4 ; X.sup.1 --X.sup.2 is CHR.sup.1 --CH, CR.sup.1 .dbd.CH, NR.sup.1 --CH, S(O).sub.u --CH or O--CH; X.sup.3 is CR.sup.5 R.sup.5 ', NR.sup.5, S(O).sub.u or O; R.sup.2 is --OR', --NR'R", --NR'SO.sub.2 R'", --NR'OR', --OCR'.sub.2 C(O)OR', --OCR'.sub.2 OC(O)--R', --OCR'.sub.2 C(O)NR'.sub.2, CF.sub.3 or --COCR'.sub.2 R.sup.2 '; R.sup.3, R.sup.4 and R.sup.7 are independently H, halo, --OR.sup.12, --SR.sup.12, --CN, --NR'R.sup.12, --NO.sub.2, --CF.sub.3, CF.sub.3 S(O).sub.r --, --CO.sub.2 R', --CONR'.sub.2, R.sup.14 --C.sub.0-6 alky-, R.sup.14 --C.sub.1-6 oxoalkyl-, R.sup.14 --C.sub.2-6 alkenyl-, R.sup.14 --C.sub.2-6 alkynyl-, R.sup.14 --C.sub.0-6 alkyloxy-, R.sup.14 --C.sub.0-6 alkylamino- or R.sup.14 --C.sub.0-6 alkyl--S(O).sub.r --; R.sup.6 is W--(CR'.sub.2).sub.q --Z--(CR'R.sup.10)--U--(CR'.sub.2).sub.s --V-- or W'--(CR'.sub.2).sub.Type: GrantFiled: December 19, 1997Date of Patent: December 28, 1999Assignee: SmithKline Beecham CorporationInventors: William E. Bondinell, William H. Miller
-
Patent number: 5998438Abstract: Described herein are compounds selective for a 5-HT.sub.1D -like receptor, which have the general formula: ##STR1## wherein A is selected from a six-membered, non-aromatic, optionally substituted carbocycle and a six-membered, non-aromatic, optionally substituted heterocycle having one or two heteroatoms selected from O, S, SO, SO.sub.2 and N.sup.4 ;R.sup.1 is selected from H and OH;n is 0 or 1 as permited by chemical structure;R.sup.2 is selected from CR.sup.5 CR.sup.6 CH.sub.2 NR.sup.7 R.sup.8 or a group of formula II, III or IV: ##STR2## R.sup.3 is selected from H and benzoyl; R.sup.4 is selected from H, loweralkyl, benzyl, loweralkylcarbonyl, loweralkylaminocarbonyl, loweralkylaminothiocarbonyl, loweralkanoyl, loweralkylaminoimide and loweralkoxy-substituted loweralkylene;R.sup.5 and R.sup.6 are independently selected from H, loweralkoxy and hydroxy;R.sup.7 and R.sup.8 are independently selected from H and loweralkyl or R.sup.7 and R.sup.Type: GrantFiled: November 21, 1997Date of Patent: December 7, 1999Assignee: Allelix Biopharmaceuticals, Inc.Inventors: Abdelmalik Slassi, Louise Edwards, Qingchang Meng, Sumanas Rakhit